Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Developers remaining in the daunting weight loss space are pinning their hopes on a new wave of locally acting drugs with the hope that gut-selective mechanisms will show better efficacy combined with fewer safety concerns than the three centrally acting obesity candidates recently rebuffed by FDA.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS004720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel